TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats.

Int J Hypertens · 2011 · PMC3253485 · PMID 22235363

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Further, a clear trend indicating less severe grade of tubules with cast and better maintained normal structure of tubules were observed in TRC120038- (1.65 ± 0.15 and 2.04 ± 0.18, resp.) and candesartan- (1.79 ± 0.12 and 2.21 ± 0.16, resp.) treated rats as compared to the vehicle-treated (2.18 ± 0.26 and 1.91 ± 0.25, resp.) ob-ZSF1 rats ( Figure 7 ).

also in 19,460 other papers

a positive trendno p-value reported

Though not significant, a positive trend towards TRC120038 treatment-related improvement was observed in the media-to-lumen ratio of intrarenal artery with respect to other two treatment groups. 3.2.5.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.